[Leish-l] RES: testing vaccinated dogs for immunopotentiation
Jennie Blackwell
jmb37 at cam.ac.uk
Wed Oct 5 20:46:13 BRT 2011
I doubt it. Treatment might but if the mum was already infected and passed the parasite to the foetus I don't see how a vaccine would work to clear the parasite from the foetus!
Slightly different question as to whether vaccinating mums will give them sufficient protection to not pass the parasite to the pup in utero should they get infected themselves after vaccination.
Cheers all, Jennie
Jenefer M. Blackwell
TICHR, CCHR, UWA
Phone: +61 8 94897910
From my iPhone
On 29 Sep 2011, at 00:36, "Chang, Kwang-Poo" <KwangPoo.Chang at rosalindfranklin.edu> wrote:
> Of interest is the question of whether vaccination would clear the infection of the pub, which has congenitally inherited L infantum ?
>
> KP
>
> From: Petersen, Christine A [V PTH] [mailto:kalicat at iastate.edu]
> Sent: Wednesday, September 28, 2011 11:23 AM
> To: Chang, Kwang-Poo; TECSA - Luiz Ristow; John David
> Cc: leish-l at lineu.icb.usp.br; Petersen, Christine A [V PTH]
> Subject: RE: [Leish-l] RES: testing vaccinated dogs for immunopotentiation
>
> The reference for this article is: http://www.ncbi.nlm.nih.gov/pubmed/21532741
> As it was published in a PLoS journal its free access to all.
> Based on our studies and recent ones from Brazil, I do believe that to remove Leish from the canine reservoir, transmission from mom to pup will need to be addressed.
> Christy Petersen
>
> From: Chang, Kwang-Poo [mailto:KwangPoo.Chang at rosalindfranklin.edu]
> Sent: Wednesday, September 28, 2011 10:20 AM
> To: TECSA - Luiz Ristow; John David
> Cc: leish-l at lineu.icb.usp.br; Petersen, Christine A [V PTH]
> Subject: RE: [Leish-l] RES: testing vaccinated dogs for immunopotentiation
>
> Christine Petersen published an article about transplacental transmission of L infantum in the USA canine leishmaniasis. I just wonder about the implication of this finding in considering vaccination against the disease transmitted this way ?
>
> KP
>
> From: leish-l-bounces at lineu.icb.usp.br [mailto:leish-l-bounces at lineu.icb.usp.br] On Behalf Of TECSA - Luiz Ristow
> Sent: Wednesday, September 28, 2011 9:08 AM
> To: 'John David'
> Cc: leish-l at lineu.icb.usp.br
> Subject: [Leish-l] RES: testing vaccinated dogs for immunopotentiation
>
> Hi !
>
> There are these papers about
> These need a very critical reading to discuss
> This discussion with all about the matter and these papers is very welcome! (at least for me!)
> Regards for all
> Luiz Ristow
>
> <image001.gif>
>
> De: leish-l-bounces at lineu.icb.usp.br [mailto:leish-l-bounces at lineu.icb.usp.br] Em nome de John David
> Enviada em: segunda-feira, 26 de setembro de 2011 18:44
> Para: Dr GR Rajasekariah
> Cc: leish-l at lineu.icb.usp.br; Carlos Gouvea; hubert mazure; smithyman at cellabs.com.au
> Assunto: Re: [Leish-l] testing vaccinated dogs for immunopotentiation
>
> I think that for any vaccine developed to protect dogs against VL, but which is also meant to prevent transmission of VL to humans, the developers should show that after the vaccinated dog has been challenged with Leishmania, it does not transmit Leishmania to sand flies.
> John R David, M.D.
> Richard Pearson Strong Professor Emeritus
> Department of Immunology and Infectious Diseases
> Harvard School of Public Health
> Professor of Medicine, Harvard Medical School
> 300 W. 23rd Street, Apt. 13K
> New York, NY, 10011
> Tel: 212 414 8646
> Email: jdavid at hsph.harvard.edu
>
>
> On Sep 19, 2011, at 12:04 AM, Dr GR Rajasekariah wrote:
>
>
> Hello EveryOne,
> I am responding to the topic on European VL Dog vaccine.
> It is a great challenge in devising a protective vaccine against visceral leishmaniasis in dogs. This point equally applies the same challenge for human situation.
> Because Th-2 response is so dominant during VL infection, modulating Th-2 into Th-1 response is a big challenge to immunologists.
>
> Key points lies in the presentation of appropriate antigen in appropriate dose to stimulate the Th-1 dependent protective immune response.
> I understand several vaccines are in the market and real efficacy of these vaccines will come out once introduced to field conditions.
>
> I just wanted to inform you that we have a suitable antibody kit for testing the immunopotentiation in dogs following vaccination of dogs.
> Our assay is based on the released promastigote antigens.
> It is a highly sensitive assay.
> Currently we supply reagents for determination of total IgG antibodies in serum.
> If any particular group is interested then we are able to provide appropriate reagent for detection of specific IgG2 and other isotype specific antibody detection.
> Because our antibody detection ELISA is based on the exo-antigens such an ELISA would be of exceptional type for measuring antibody response in vaccinated animals.
> Highly suitable for diagnosing dogs responded to vaccines.
>
> Recently I came to know that some of commercial kits were found to be not useful for detecting seroconversion in dogs vaccinated with FML vaccine (Leish-Immune) in Brazil.
> Because we use released antigens in our kit, any such problems will overcome if they use Canine Leish IgG CELISA (Manufacturer Cellabs Pty Ltd Brookvale NSW Australia email sales at cellabs.com.au).
> If any one is interested to know more about our antibody detection ELISA based on exo-antigens please contact us.
>
> This is for your kind information.
>
> Dr GR Rajasekariah
> Sydney
> Australia
> raj at cellabs.com.au
>
>
>
>
>
>
> ----- Original Message ----- From: <leish-l-request at lineu.icb.usp.br>
> To: <leish-l at lineu.icb.usp.br>
> Sent: Wednesday, August 10, 2011 5:18 PM
> Subject: Leish-l Digest, Vol 44, Issue 3
>
> Send Leish-l mailing list submissions to
> leish-l at lineu.icb.usp.br
>
> To subscribe or unsubscribe via the World Wide Web, visit
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> or, via email, send a message with subject or body 'help' to
> leish-l-request at lineu.icb.usp.br
>
> You can reach the person managing the list at
> leish-l-owner at lineu.icb.usp.br
>
> When replying, please edit your Subject line so it is more specific
> than "Re: Contents of Leish-l digest..."
>
>
> Today's Topics:
>
> 1. European VL Dog Vaccine - CaniLeish?: (jeffrey shaw)
> 2. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)
> 3. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)
>
>
> ----------------------------------------------------------------------
>
> Message: 1
> Date: Tue, 9 Aug 2011 15:18:44 +0000
> From: jeffrey shaw <jayusp at hotmail.com>
> Subject: [Leish-l] European VL Dog Vaccine - CaniLeish?:
> To: Leish-L <leish-l at lineu.icb.usp.br>
> Message-ID: <COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl>
> Content-Type: text/plain; charset="windows-1252"
>
>
> CaniLeish?:
> The European Commission granted a marketing authorisation valid throughout the European Union, for CaniLeish to Virbac S.A. on 14/03/2011.
> This vaccine, CaniLeish?, will initially be launched in Portugal at the end of the first half of 2011. This will be followed rapidly by launches in other countries in the endemic area: Spain, France, Greece and Italy (not in chronological order). This roll-out takes account of the geographical prevalence of the disease and the time required to build vaccine production up to full capacity. The launch in Northern European countries from where there is a flow of summer visitors to the endemic area will be part of a second phase.
> The basis of this vaccine are excreted proteins plus a saponin adjuvant purified from Quil-A. Its efficacy was determined in a 2 year open field trial.
> The vaccine is given to dogs as three injections, three weeks apart, under the skin. The first injection can be given from six months of age, the second injection is given three weeks later and the third three weeks from the second one. Afterward a single ?booster? should be given every year to maintain protection.
> -------------- next part --------------
> An HTML attachment was scrubbed...
> URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e/attachment-0001.htm>
>
> ------------------------------
>
> Message: 2
> Date: Wed, 10 Aug 2011 13:07:17 +0600
> From: Moazzem Hossain <directordcbd at gmail.com>
> Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network
> To: jeffrey shaw <jayusp at hotmail.com>, "Prof. Paul Kaye"
> <paul.kaye at york.ac.uk>
> Cc: "Prof. Dr. Moazzem Hossain" <profdrmoazzemhossain at gmail.com>,
> Leish-L <leish-l at lineu.icb.usp.br>
> Message-ID:
> <CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.com>
> Content-Type: text/plain; charset=windows-1252
>
> 10 Aug 2011
>
> Dear Professor Paul Kaye,
>
> Thank you for your email. Please find attached our supportive letter
> of interest for Leishmaniasis Pathology Network.
> Looking forward for your kind response.
>
> Best regards.
>
>
> --
> *Prof. Dr. Moazzem Hossain *
> Ex - Director Disease Control
> Ministry of Health & Family Welfare
> Government of Bangladesh
> *Mailing address*:
> Founder Chairman and Project Director
> Institute of Allergy & Clinical Immunology of Bangladesh (IACIB)
> Room 4 - 5 (2nd Floor), Green Super Market, Green Road
> Dhaka -1205, Bangladesh.
> Phone:880-2-8115646 (O )
> 880-1715038551(Mobile)
> Email: directordcbd at gmail.com
>
>
>
>
>
>
>
>
> On 8/9/11, jeffrey shaw <jayusp at hotmail.com> wrote:
>
>
>
> Date: Tue, 9 Aug 2011 11:58:52 +0100
> From: paul.kaye at york.ac.uk
>
> Subject: Leishmaniasis Pathology Network
>
>
>
>
>
>
>
>
>
> Dear all,
> Invitation to participate in a global pathology
> network for
> research and training in leishmaniasis (LeishPathNet)
> You may recall the Dormy House meeting in 2008
> and some of
> the plans we put forward? Over
> the past
> couple years, I have also spoken more to a few of you about one
> idea that was
> formulated at Dormy, namely of setting up a digital pathology
> network. I have
> also had numerous discussions with the major equipment
> manufacturers to see if
> any of them would be supportive of helping us to develop such an
> initiative. There have
> been two major
> develoments recently. First,
> Carl Zeiss
> is willing to work with us to set up an integrated global digital
> pathology
> network (providing a significant financial and technical
> contribution) and
> second, the Wellcome Trust is willing to review a pre-proposal to
> fund the
> initiative through their new Biomedical Resources Grant scheme
> (http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Strategic-awards-and-initiatives/wtdv031727.htm)
> .
> I have attached an outline of the project that
> I had sent to
> the Trust for their initial views, which I think is reasonably
> self-explanatory.
> They appeared very
> enthusiastic! The main
> question now is whether enough of
> you are still supportive? [ I will also be sending this email to
> others, but please feel free to circulate ]
>
>
> I think the
> project will be
> challenging, but success could have a real impact on the way we
> conduct
> business. It should serve not only as a vehicle to enhance
> research in
> leishmaniasis, but the model would be equally applicable across
> a broad range
> of diseases and global challenges (with leishmaniasis setting
> the pace).
> If we wish to
> proceed, the requirements
> are that we submit a pre-proposal to the Trust by Oct 18th 2011.
> This pre-proposal is short (4 sections of 350 words) and
> requires
> letters of support from the community.
> If you are
> supportive of the idea that
> we try to take this forward (and there is plenty of scope for
> later iteration
> of the detail), I would be grateful if you could please provide
> me with a
> letter of support by September
> 12th
> 2011, indicating whether you would like to be a network
> partner if the bid
> is successful. You could
> also be
> supportive but not wish to become directly involved at this
> stage, and such
> letters are equally valuable. Your letter might also stress the
> added value
> that the network could provide, its importance for research and
> training and/or
> for progressing the translational agenda.
> It would also be an opportunity to indicate whether your
> group (or
> institute, if multiple groups) would be interested in bidding to
> be one of the
> initial ?designated laboratories?.
> If there is
> sufficient support to
> proceed and if subsequently the pre-proposal is successful (we
> will know on 22nd
> Nov), then I will need a few volunteers to help finalise the
> full proposal,
> which will be due on Jan 26th 2012.
> A funding decision will be made on May 26th
> 2012.
> Best wishes
> and of course I am happy to
> discuss any points further (though I will be out of the UK from
> Aug 10 ?Sept
> 12)
> Paul
>
>
>
>
>
>
>
> --
> Professor Paul Kaye, Ph.D., FRCPath.
> Deputy Dean (Research), Hull York Medical School, and
> Director, Centre for Immunology and Infection
> Department of Biology and Hull York Medical School
> University of York
> Wentworth Way
> York YO10 5YW
> United Kingdom
>
> Tel: +44 (0)1904 328840
> Fax: +44 (0)1904 328844
> Email: paul.kaye at york.ac.uk <mailto:paul.kaye at york.ac.uk>
>
> Centre Administrator and PA: Elizabeth Greensted
> Tel: 01904 328845
> Email: liz.greensted at york.ac.uk <mailto:liz.greensted at york.ac.uk>
>
> Centre Email: cii at york.ac.uk <mailto:cii at york.ac.uk>
>
> Centre website: http://www.york.ac.uk/cii
>
> Times Higher Education University of the Year 2010
>
> Email disclaimer: http://www.york.ac.uk/docs/disclaimer/email.htm
>
>
>
>
> ------------------------------
>
> Message: 3
> Date: Wed, 10 Aug 2011 13:06:47 +0600
> From: Moazzem Hossain <directordcbd at gmail.com>
> Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network
> To: jeffrey shaw <jayusp at hotmail.com>, "Prof. Paul Kaye"
> <paul.kaye at york.ac.uk>
> Cc: "Prof. Dr. Moazzem Hossain" <profdrmoazzemhossain at gmail.com>,
> Leish-L <leish-l at lineu.icb.usp.br>
> Message-ID:
> <CAE-TCmQNUkZdNE5w+Z20bjLC-=vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.com>
> Content-Type: text/plain; charset="windows-1252"
>
> 10 Aug 2011
>
> Dear Professor Paul Kaye,
>
> Thank you for your email. Please find attached our supportive letter
> of interest for Leishmaniasis Pathology Network.
> Looking forward for your kind response.
>
> Best regards.
>
>
> --
> *Prof. Dr. Moazzem Hossain *
> Ex - Director Disease Control
> Ministry of Health & Family Welfare
> Government of Bangladesh
> *Mailing address*:
> Founder Chairman and Project Director
> Institute of Allergy & Clinical Immunology of Bangladesh (IACIB)
> Room 4 - 5 (2nd Floor), Green Super Market, Green Road
> Dhaka -1205, Bangladesh.
> Phone:880-2-8115646 (O )
> 880-1715038551(Mobile)
> Email: directordcbd at gmail.com
>
>
>
>
>
>
>
>
> On 8/9/11, jeffrey shaw <jayusp at hotmail.com> wrote:
>
>
>
> Date: Tue, 9 Aug 2011 11:58:52 +0100
> From: paul.kaye at york.ac.uk
>
> Subject: Leishmaniasis Pathology Network
>
>
>
>
>
>
>
>
>
> Dear all,
> Invitation to participate in a global pathology
> network for
> research and training in leishmaniasis (LeishPathNet)
> You may recall the Dormy House meeting in 2008
> and some of
> the plans we put forward? Over
> the past
> couple years, I have also spoken more to a few of you about one
> idea that was
> formulated at Dormy, namely of setting up a digital pathology
> network. I have
> also had numerous discussions with the major equipment
> manufacturers to see if
> any of them would be supportive of helping us to develop such an
> initiative. There have
> been two major
> develoments recently. First,
> Carl Zeiss
> is willing to work with us to set up an integrated global digital
> pathology
> network (providing a significant financial and technical
> contribution) and
> second, the Wellcome Trust is willing to review a pre-proposal to
> fund the
> initiative through their new Biomedical Resources Grant scheme
> (http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Strategic-awards-and-initiatives/wtdv031727.htm)
> .
> I have attached an outline of the project that
> I had sent to
> the Trust for their initial views, which I think is reasonably
> self-explanatory.
> They appeared very
> enthusiastic! The main
> question now is whether enough of
> you are still supportive? [ I will also be sending this email to
> others, but please feel free to circulate ]
>
>
> I think the
> project will be
> challenging, but success could have a real impact on the way we
> conduct
> business. It should serve not only as a vehicle to enhance
> research in
> leishmaniasis, but the model would be equally applicable across
> a broad range
> of diseases and global challenges (with leishmaniasis setting
> the pace).
> If we wish to
> proceed, the requirements
> are that we submit a pre-proposal to the Trust by Oct 18th 2011.
> This pre-proposal is short (4 sections of 350 words) and
> requires
> letters of support from the community.
> If you are
> supportive of the idea that
> we try to take this forward (and there is plenty of scope for
> later iteration
> of the detail), I would be grateful if you could please provide
> me with a
> letter of support by September
> 12th
> 2011, indicating whether you would like to be a network
> partner if the bid
> is successful. You could
> also be
> supportive but not wish to become directly involved at this
> stage, and such
> letters are equally valuable. Your letter might also stress the
> added value
> that the network could provide, its importance for research and
> training and/or
> for progressing the translational agenda.
> It would also be an opportunity to indicate whether your
> group (or
> institute, if multiple groups) would be interested in bidding to
> be one of the
> initial ?designated laboratories?.
> If there is
> sufficient support to
> proceed and if subsequently the pre-proposal is successful (we
> will know on 22nd
> Nov), then I will need a few volunteers to help finalise the
> full proposal,
> which will be due on Jan 26th 2012.
> A funding decision will be made on May 26th
> 2012.
> Best wishes
> and of course I am happy to
> discuss any points further (though I will be out of the UK from
> Aug 10 ?Sept
> 12)
> Paul
>
>
>
>
>
>
>
> --
> Professor Paul Kaye, Ph.D., FRCPath.
> Deputy Dean (Research), Hull York Medical School, and
> Director, Centre for Immunology and Infection
> Department of Biology and Hull York Medical School
> University of York
> Wentworth Way
> York YO10 5YW
> United Kingdom
>
> Tel: +44 (0)1904 328840
> Fax: +44 (0)1904 328844
> Email: paul.kaye at york.ac.uk <mailto:paul.kaye at york.ac.uk>
>
> Centre Administrator and PA: Elizabeth Greensted
> Tel: 01904 328845
> Email: liz.greensted at york.ac.uk <mailto:liz.greensted at york.ac.uk>
>
> Centre Email: cii at york.ac.uk <mailto:cii at york.ac.uk>
>
> Centre website: http://www.york.ac.uk/cii
>
> Times Higher Education University of the Year 2010
>
> Email disclaimer: http://www.york.ac.uk/docs/disclaimer/email.htm
>
>
> -------------- next part --------------
> A non-text attachment was scrubbed...
> Name: Letter Leish UK.doc
> Type: application/msword
> Size: 46080 bytes
> Desc: not available
> URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae6a/attachment.doc>
>
> ------------------------------
>
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
>
> End of Leish-l Digest, Vol 44, Issue 3
> **************************************
>
>
>
>
>
> =======
> Email scanned by PC Tools - No viruses or spyware found.
> (Email Guard: 7.0.0.26, Virus/Spyware Database: 6.18330)
> http://www.pctools.com/
> =======
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
>
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20111006/f1f99499/attachment-0001.htm>
More information about the Leish-l
mailing list